Mehmet Samur

Senior Research Scientist

Dana-Farber Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Transcription factors and their cofactors are major and selective nononcogene dependencies in multiple myeloma cells. By performing a gain-of-function perturbation screen in human multiple myeloma cell lines, we identified the inhibitor of DNA binding ( ID ) genes as putative suppressors of multiple myeloma cell fitness. Among them, ID2 was found to be downregulated in multiple myeloma patient cells and acted as a tumor suppressor by directly binding and repressing the basic helix-loop-helix factor TCF3, also known as E2A. Lower ID2 expression in multiple myeloma cells conferred a proliferative advantage by increasing TCF3 activity, leading to a dependency on this transcription factor. In contrast, ID2 overexpression reduced TCF3 binding to DNA, which resulted in cell-cycle arrest and a halt in multiple myeloma cell proliferation. The myeloma bone marrow milieu supported this process by further decreasing the expression of ID2 and enhancing TCF3 activity, partly via IL6, revealing a mechanism by which the tumor microenvironment affects multiple myeloma cell behavior. Significance: Multiple myeloma cells exploit the oncogenic and proliferative potential of TCF3 by downregulating the transcriptional regulator ID2, a process facilitated by the bone marrow microenvironment.

Year:

2026

Supplementary Figure S1. Discovery of ID2 as a putative tumor suppressor in MM. Supplementary Figure S2. ID2 expression causes cell cycle arrest in MM cells. Supplementary Figure S3. Induced ID2 expression in MM cells is associated with senescence-like features. Supplementary Figure S4. TCF3 is a highly expressed selective dependency in MM cells. Supplementary Figure S5. Depletion of TCF3 phenocopies effects of ID2 overexpression in MM cells. Supplementary Figure S6. The bone marrow milieu has a role in supporting TCF3 activity in MM.

Year:

2026

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional prognostic factors based on data from patients treated with older therapies no longer capture prognosis accurately in the contemporary era of novel triplet or quadruplet therapies. Therefore, risk stratification requires refinement in the context of available and investigational treatment options in routine practice and clinical trials, respectively. The current identification of high-risk MM (HRMM) in routine practice is based on the Revised International Staging System, which stratifies patients using a combination of widely available serum biomarkers and chromosomal abnormalities assessed via fluorescence in situ hybridization. In recent years, a substantial body of evidence concerning additional clinical, biological, and molecular/genomic prognostic factors has accumulated, along with new MM risk stratification tools and consensus reports. The International Myeloma Society, along with the International Myeloma Working Group, convened an Expert Panel with the primary aim of revisiting the definition of HRMM and formulating a practical and data-driven consensus definition, based on new evidence from molecular/genomic assays, updated clinical data, and contemporary risk stratification concepts. The Panel proposes the following Consensus Genomic Staging (CGS) of HRMM which relies upon the presence of at least one of these abnormalities: (1) del(17p), with a cutoff of >20% clonal fraction, and/or TP53 mutation; (2) an IgH translocation including t(4;14), t(14;16), or t(14;20) along with 1q+ and/or del(1p32); (3) monoallelic del(1p32) along with 1q+ or biallelic del(1p32); or (4) β2 microglobulin ≥5.5 mg/L with normal creatinine (<1.2 mg/dL).

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Multiple myeloma (MM) is an incurable malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment. To investigate immune factors driving treatment response and resistance, we conducted multi-omics profiling including CD138 neg single-cell RNA sequencing of 243 bone marrow samples from 102 patients (631,226 cells) and CD138 pos bulk RNA and whole-genome sequencing from 209 samples. Longitudinal analyses revealed that interferon gamma signaling impairs T cell memory after autologous stem cell transplant, while naïve B cell abundance and immunoglobulin diversity correlated with improved progression-free survival (HR = 0.48, p = 2.3e -4 ). At disease progression, MM cells upregulated cancer-testis antigens and immune effector genes, with concurrent B cell depletion, enrichment of myeloid-derived suppressor cell genes in monocytes, and T cell exhaustion. These findings highlight dynamic immune-tumor interactions, identifying naïve B cell reconstitution as a biomarker of durable response, and cancer-testis antigens as potential targets for high-risk disease at progression. Statement of Significance Longitudinal profiling of multiple myeloma and the immune microenvironment revealed dynamic immune-tumor interactions across the disease course. Dysfunctional CD8⁺ T cells limited memory formation post-transplant, while naïve B recovery associated with sustained treatment response. At progression, cancer-testis antigen expression associated with immunosuppression, revealing novel mechanisms of immune escape.

Year:

2025

Supplementary Figure S4. Impact of pharmacological inhibition (ND-630 and ND-646) and ACC1 knockdown on MM cell viability, proliferation, and de novo lipogenesis (DNL) rates in MYC overexpressed MM cells.

Year:

2025

Purpose: In multiple myeloma, tumor cells reprogram metabolic pathways to sustain growth and monoclonal immunoglobulin production. This study examines acetyl-CoA carboxylase 1 ( ACC1 ), the enzyme driving the rate-limiting step in de novo lipogenesis, in multiple myeloma metabolic reprogramming, particularly in c- MYC ( MYC )–driven subtypes. Experimental Design: ACC1 expression was evaluated across multiple myeloma genetic subgroups, focusing on MYC translocations. Functional studies using ACC1 inhibitors and genetic knockdown assessed multiple myeloma cell growth, lipid synthesis, and metabolic homeostasis in vitro and in vivo . The role of MYC overexpression in ACC1 sensitivity was examined, with palmitate rescue experiments. Lipidomic analysis and assessments of endoplasmic reticulum (ER) stress, protein translation, and oxidative damage elucidated underlying mechanisms. Results: ACC1 was overexpressed in MYC -translocated multiple myeloma. Its inhibition or knockdown reduced multiple myeloma cell growth in vitro and in vivo , particularly in MYC- overexpressing cells. ACC1 knockdown suppressed de novo lipid synthesis, partially rescued by palmitate. Lipidomic disruptions increased cholesterol ester desaturation and altered phospholipid ratios, inducing ER stress, impaired translation, protein carbonylation, oxidative damage, and apoptosis. Conclusions: ACC1 is a metabolic vulnerability in MYC -driven multiple myeloma. Inhibiting ACC1 disrupts lipid homeostasis, induces ER stress, and causes oxidative damage, impairing cell survival. Targeting lipid synthesis pathways, especially in MYC -dependent subtypes, offers a promising therapeutic strategy for multiple myeloma.

Year:

2025

To study the heterogeneity of transcriptional and genomic traits that underlie the clinical presentation of untreated Waldenstrom’s Macroglobulinemia (WM), we performed multi-omic studies in 249 treatment-naive patients with WM. For all patients, RNASeq was performed on CD19-selected bone marrow (BM) MYD88 mutated samples as well as 13 paired CD19 + CD27 − and CD19 + CD27 + peripheral blood samples from healthy donors. Whole exome sequencing (WES) was also analyzed on paired tumor and germline DNA for 229 of these patients and DNA methylation status was assessed by enhanced reduced representational bisulfite sequencing (ERRBS) for 32 samples. The ERRBS and transcriptional data identified two distinct cells of origin for WM leading to two independent WM subtypes known as B-cell Like (BCL) and Plasma Cell Like (PCL). A third subtype, Early WM, was observed primarily in smoldering WM and was present in both ERRBS clusters identifying it as a transcriptional state common to early BCL and PCL. We further identified the WM Evolutionary Score (EScore), a gene signature common to all samples that predicted time to first therapy and corresponded with progression to symptomatic WM. Analysis of the EScore revealed a subclone expressing pre-B-cell, T-cell, stem cell and myeloid markers that was confirmed by flow cytometry and detected in early (smoldering) WM with subpopulations persisting with WM evolution. Our findings have important implications for WM pathogenesis. The evolution from the Early WM subtype to either BCL or PCL and EScore explains much of the genomic, transcriptional and clinical heterogeneity of WM including clinical outcomes to primary therapy.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (43)

Shaji Kumar

Medical College of Wisconsin

UNITED STATES
View details

Karthik Ramasamy

Cancer Divisional Lead

University of Oxford

UNITED KINGDOM
View details

Jill Corre

-

FRANCE
View details

Brian Walker

Professor

University of Miami

UNITED STATES
View details

Steven Treon

Professor

Harvard Medical School

UNITED STATES
View details

Adam Sperling

Assistant Professor

Stanford University

UNITED STATES
View details

Manoj Bhasin

Director, Genomics, Proteomics, Bioinformatics and Single cell Biology

Children's Healthcare of Atlanta

UNITED STATES
View details

Charles B. Epstein

Broad Institute

UNITED STATES
View details

Ioannis Vlachos

Broad Institute

UNITED STATES
View details

Massimo Loda

Chair

Weill Cornell Medical College

UNITED STATES
View details

David Avigan

Vice Chair of Oncology

Dana-Farber Cancer Institute

UNITED STATES
View details

Anil Aktas Samur

Senior Scientist

Dana-Farber Cancer Institute

UNITED STATES
View details

Martin Kaiser

Professor of Haematology

The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust

UNITED KINGDOM
View details

Shirong Liu

Senior Scientist

Dana-Farber Cancer Institute

UNITED STATES
View details

Samir Parekh

Director, Center of Excellence for Multiple Myeloma

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Robert Orlowski

Florence Maude Thomas Cancer Research Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

James Dunford

University of Oxford

UNITED KINGDOM
View details

Eugenio Morelli

Assistant Professor

Università degli Studi di Torino

ITALY
View details

jun qi

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Sagar Lonial

-

UNITED STATES
View details

Alice Cleynen

Directrice de Recherche CNRS

Université Grenoble Alpes

FRANCE
View details

Ajay K. Nooka

Professor

Emory University

UNITED STATES
View details

Cirino Botta

Assistant Professor of Hematology

University of Palermo

ITALY
View details

Mattia D'Agostino

Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino

ITALY
View details

Ravi Vij

Washington University School of Medicine

UNITED STATES
View details

Giorgio Inghirami

Professor

Weill Cornell Medical College

UNITED STATES
View details

Romain Lannes

Whitehead Institute for Biomedical Research

UNITED STATES
View details

Annamaria Gulla

Group leader

Candiolo Cancer Institute, FPO-IRCCS

ITALY
View details

Madhav V. Dhodapkar

-

UNITED STATES
View details

Raphael Szalat

Assistant professor

Boston University

UNITED STATES
View details

Herve Avet-Loiseau

-

FRANCE
View details

Bruno David Lourenço Paiva

Clinica Universidad de Navarra

SPAIN
View details

Jorge Castillo

Clinical Director, Bing Center for Waldenstrom Macroglobulinemia

Dana-Farber Cancer Institute

UNITED STATES
View details

Edgar Ernesto Gonzalez Kozlova

Assistant Professor

-

UNITED STATES
View details

Lawrence Boise

Professor

Emory University

UNITED STATES
View details

Norma C. Gutiérrez

-

SPAIN
View details

Marc S. Raab

University Hospital Heidelberg

GERMANY
View details

Mani Larijani

Shrum Chair in Biological Mechanisms of Disease & Associate Professor

Simon Fraser University

CANADA
View details

Daniel W. Sherbenou

Associate Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Adam P Cribbs

Group leader in systems biology and MRC Career Development Fellow

-

UNITED KINGDOM
View details

Jonathan Keats

Director of Bioinformatics / Assistant Professor

Translational Genomics Research Institute

UNITED STATES
View details

Markus Hansson

Professor

Sahlgrenska universitetssjukhuset

SWEDEN
View details

Ari M. Melnick

Director

Josep Carreras Leukaemia Research Institute

SPAIN
View details